Efficacy of Osteopathic Treatment on the Side Effects of Curative Treatments of Lymphoblastic Leukemia in Pediatrics

NCT05664230 — Unknown, 15 participants, Assistance Publique - Hôpitaux de Paris

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT05664230, acronym Leucosteo
StatusUnknown
Study typeObservational
Enrollment15 (Estimated)
SponsorAssistance Publique - Hôpitaux de Paris (Other)
ConditionsLymphoblastic Leukemia
Interventionsosteopathy (Other)
Datesstart 2023-01-01 (estimated), primary completion 2023-07-01 (estimated), completion 2023-08-01 (estimated), first posted 2022-12-23, last updated 2022-12-23
Locations1 site in France

Related Papers Related Patents Related Grants Related Experts
All trials for Lymphoblastic Leukemia All trials of osteopathy

-Summary

During the curative treatment of cancer, pain often remains the dominant symptom affecting the physical and psychological state of the patient.

Osteopathy is an exclusively manual practice whose goal is to compensate for mobility dysfunctions of the tissues of the human body. It can be used as a complementary treatment for cancer pain when pain medications are not enough.

The aim of this study is to examine the effectiveness of osteopathy in reducing pain intensity and improving quality of life in patients treated for pediatric acute lymphoblastic leukemia.

Expand all sections  ·  Collapse all

+Detailed description

During the curative treatment of cancer, pain often remains the dominant symptom affecting the physical and psychological state of the patient.

Osteopathy is an exclusively manual practice whose goal is to compensate for mobility dysfunctions of the tissues of the human body. It can be used as a complementary treatment for cancer pain when pain medications are not enough.

The aim of this study is to examine the effectiveness of osteopathy in reducing pain intensity and improving quality of life in patients treated for pediatric acute lymphoblastic leukemia.

Primary objective :

To evaluate the effectiveness of five osteopathy sessions at regular intervals on the characteristics of the pain felt in patients aged 1 to 10 years treated for acute lymphoblastic leukemia using the HEDEN scale (Hetero-Evaluation Pain Child).

+Arms and interventions

  • osteopathy (Other), also known as osteopathy session: five osteopathy sessions

+Outcome measures

Primary outcomes

  • Evaluate the effectiveness of 5 weekly osteopathy sessions at regular intervals from week 1 to week 5 on the characteristics of the pain felt in patients aged 1 to 10 years treated for acute lymphoblastic leukemia using the HEDEN scale. [5 weeks]: HEDEN (Hetero-Evaluation Pain Child) score before and after each intervention

Secondary outcomes

  • Evaluate the effectiveness of 5 weekly osteopathy sessions at regular intervals from week 1 to week 5 on the intensity of the pain felt in patients aged 4 to 10 years treated for acute lymphoblastic leukemia using the face scale: FPS -R. [5 weeks]: FPS-R (Face Pain Scale-Revised) score before and after each osteopathy session
  • To study the variations in quality of life at inclusion and at the end of the study using the PedsQL™ (questionnaire quality of life in paediatrics). [5 weeks]: PedsQL™ Questionnaire quality of life in paediatrics

+Eligibility

Sex: All, ages: 1 Year to 10 Years

Inclusion Criteria:

* Patient managed and treated with a diagnosis of acute lymphoblastic leukemia
* Patient between 1 and 10 years of age
* Patient with pain at inclusion, or pain at diagnosis related to leukemia
* Social security affiliation or entitlement
* Signature of informed consent by both parents

Exclusion Criteria:

* No pain reported at the time of management or diagnosis
* Surgery less than 30 days old
* Patient with another contraindication to osteopathic treatment (worsening of the condition, bleeding syndrome), or a psychiatric pathology that prevents the scales from being used.

+Locations (1)

FacilityCityCountryStatus
Robert Debré HospitalParisFrance

+Investigators

  • Benoit BRETHON, MD, Principal investigator, Assistant Publique Hopitaux de Paris